Cargando…

Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine”

Detalles Bibliográficos
Autores principales:	Giannelos, Nikolaos, Nishimwe, Marie Libérée, Lecrenier, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522720/ https://www.ncbi.nlm.nih.gov/pubmed/36163540 http://dx.doi.org/10.1007/s40273-022-01184-0

Ejemplares similares

Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022)

Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
por: Giannelos, Nikolaos, et al.
Publicado: (2023)

Healthy ageing: Herpes zoster infection and the role of zoster vaccination
por: Curran, Desmond, et al.
Publicado: (2023)

Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine
por: Grupping, Katrijn, et al.
Publicado: (2017)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older
por: Schwarz, Tino F, et al.
Publicado: (2017)

Herpes zoster following COVID-19 vaccination in an immunocompetent and vaccinated for herpes zoster adult: A two-vaccine related event?
por: Vallianou, Natalia G., et al.
Publicado: (2022)

Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines
por: de Boer, Pieter T., et al.
Publicado: (2018)

Public health impact of herpes zoster vaccination on older adults in Hong Kong
por: Chan, Paul K. S., et al.
Publicado: (2023)

Optimal gender-specific age for cost-effective vaccination with adjuvanted herpes zoster subunit vaccine in Chinese adults
por: You, Joyce H. S., et al.
Publicado: (2019)

Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies
por: Mwakingwe-Omari, Agnes, et al.
Publicado: (2023)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: A Phase III, Group-Matched, Clinical Trial
por: Grupping, Katrijn, et al.
Publicado: (2017)

Herpes Zoster Vaccination
por: Kim, Kyung Hoon
Publicado: (2013)

Herpes Zoster Vaccines
por: Harbecke, Ruth, et al.
Publicado: (2021)

Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
por: Teng, Lida, et al.
Publicado: (2022)

Severe Herpes Zoster Following Varicella Vaccination in Immunocompetent Young Children
por: Moodley, Amaran, et al.
Publicado: (2019)

The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

An update on national recommendations for the use of the adjuvanted recombinant zoster vaccine: Romy Weller
por: Parikh, R, et al.
Publicado: (2022)

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination
por: Bruxvoort, Katia J, et al.
Publicado: (2022)

Herpes zoster vaccine in Korea
por: Choi, Won Suk
Publicado: (2013)

Vaccine against herpes zoster
por: Pasternak, Jacyr
Publicado: (2013)

A Cost-Effectiveness Analysis of an Adjuvanted Subunit Vaccine for the Prevention of Herpes Zoster and Post-Herpetic Neuralgia
por: Carpenter, Christopher, et al.
Publicado: (2017)

A Cost-effectiveness Analysis of an Adjuvanted Subunit Vaccine for the Prevention of Herpes Zoster and Post-herpetic Neuralgia
por: Carpenter, Christopher F, et al.
Publicado: (2019)

An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine
por: Pirrotta, Paola, et al.
Publicado: (2021)

Varicella Vaccine Meningitis as a Complication of Herpes Zoster in Twice-Immunized Immunocompetent Adolescents
por: Ramachandran, Veena, et al.
Publicado: (2020)

Results of a Safety Pooled Analysis of an Adjuvanted Herpes Zoster Subunit Vaccine in More than 14,500 Participants Aged 50 Years or Older
por: López-Fauqued, Marta, et al.
Publicado: (2017)

Cost-Effectiveness of Herpes Zoster Vaccination
por: Sriwijitalai, Won, et al.
Publicado: (2019)

Herpes zoster after COVID vaccination
por: van Dam, C.S., et al.
Publicado: (2021)

Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial
por: Godeaux, Olivier, et al.
Publicado: (2017)

Modeled impact of the COVID-19 pandemic and associated reduction in adult vaccinations on herpes zoster in the United States
por: Curran, Desmond, et al.
Publicado: (2022)

A novel nonlive, adjuvanted herpes zoster subunit vaccine: a report on the emerging clinical data and safety profile
por: Brosio, Federica, et al.
Publicado: (2018)

Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
por: Marra, Yasmin, et al.
Publicado: (2022)

Status of Herpes Zoster and Herpes Zoster Vaccines in 2023: A position paper
por: García, José María Molero, et al.
Publicado: (2023)

12. Modeled Impact of the COVID-19 Pandemic and Associated Reduced Adult Vaccinations on Herpes Zoster in the United States
por: La, Elizabeth M, et al.
Publicado: (2021)

Herpes Zoster: the rationale for the introduction of vaccination in Italy
por: PAGANINO, C., et al.
Publicado: (2015)

Update on Recommendations for Use of Herpes Zoster Vaccine
por: Hales, Craig M., et al.
Publicado: (2014)

Vaccines for preventing herpes zoster in older adults
por: Gagliardi, Ana M. Z., et al.
Publicado: (2014)

Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine
por: Fochesato, Michel, et al.
Publicado: (2016)

Disseminated Herpes Zoster Following Protein Subunit and mRNA COVID-19 Vaccination in Immunocompetent Patients: Report of Two Cases and Literature Review
por: Lin, Chia-Shuen, et al.
Publicado: (2023)

Comparison of the Immune Effects of an mRNA Vaccine and a Subunit Vaccine against Herpes Zoster Administered by Different Injection Methods
por: Lin, Kangyang, et al.
Publicado: (2023)

Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly
por: Vink, Peter, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_voprpr7qgjteh2iqpftlto5djp